


Amendments to the Claims

Please amend the listing of claims as follows:

1. (Original) A compound of structural formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein

Ar is:

aryl or heteroaryl which may both be substituted or unsubstituted;

R_1 is independently:

hydrogen,

hydroxy,

cyano,

nitro,


halo,

alkyl,

alkoxy or

haloalkyl;

R_2 is:



each R_3 is independently:

hydrogen,
halo,
alkyl,
haloalkyl,
hydroxy,
alkoxy,
S-alkyl,
SO₂-alkyl,
O-alkenyl,
S-alkenyl,
NR₇C(O)R₇,
NR₇SO₂R₇,
N(R₇)₂
(D)-cycloalkyl,
(D)-aryl,
(D)-heteroaryl or
(D)-heterocyclyl (wherein heterocyclyl excludes a heterocyclyl containing a single nitrogen), and
wherein aryl, heteroaryl, heterocyclyl, alkyl and/or cycloalkyl may be substituted or unsubstituted, and two adjacent R_3 may form a 4- to 7-membered ring;

R₇ and R₈ are each independently:

hydrogen,
alkyl or
cycloalkyl, or
R₇ and R₈ together with the nitrogen to which they are attached form a 5- to 8-membered ring,
wherein alkyl and cycloalkyl are both unsubstituted or substituted;

D is a bond or alkyl;

X is CH or N;

Y is O or NR₇;

n is 1 - 4;
 m is 0 - 3;
 o is 0 - 2;
 p is 0 - 2;
 q is 1 or 2;
 s is 0 - 4.

2. (Original) The compound of claim 1, wherein


Ar is:

aryl which may be substituted with one to three substituents independently selected from the group consisting of cyano, nitro, perfluoroalkoxy, halo, alkyl, (D)-cycloalkyl, alkoxy and/or haloalkyl;

R₁ is independently:

hydrogen,
 hydroxy,
 halo,
 alkyl,
 alkoxy or
 haloalkyl;

R₂ is:



each R₃ is independently:

hydrogen,
 halo,
 alkyl,
 haloalkyl,
 hydroxy,
 alkoxy,
 S-alkyl or

SO₂-alkyl,
O-alkenyl or
S-alkenyl;

R₇ and R₈ are each independently:

hydrogen,
alkyl or
cycloalkyl, or

R₇ and R₈ together with the nitrogen to which they are attached form a 5- to 7-membered ring optionally containing an additional heteroatom selected from O, S and NR₄;

D is a bond or CH₂;

X is CH or N;

Y is NR₇ or O;

n is 1 or 2;

m is 1 - 3;

o is 0 or 1;

p is 0 or 1;

q is 1;

s is 1 - 3.

3. (Currently Amended) The compound of claim 1-~~or 2~~, wherein


Ar is:

phenyl or naphthyl which may be substituted with one or two substituents independently selected from the group consisting of perfluoroalkoxy, halo, alkyl, alkoxy and haloalkyl;

R₁ is independently:

hydrogen,
alkoxy,
halo or
alkyl;

R₂ is:



each R₃ is independently:

hydrogen,
hydroxy,
alkoxy,
SO₂-alkyl or
iso-propyl;

R₇ and R₈ are each independently:

hydrogen or
alkyl, or

R₇ and R₈ together with the nitrogen to which they are attached form a
6-membered ring optionally containing an additional oxygen atom;

X is CH or N;

Y is N-alkyl or O;

n is 1;

m is 1 - 3;

o is 0 or 1;

p is 0 or 1;

q is 1.


4. (Currently Amended) The compound of ~~any of claims 1 to 3~~ claim 1, wherein

Ar is:

phenyl or naphthyl which may be substituted with halo;

R₁ is hydrogen;

R₂ is:



each R₃ is independently:

hydrogen,
hydroxy,
alkoxy,
SO₂-alkyl or
iso-propyl;

R₇ and R₈ are each independently:

hydrogen or
alkyl, or

R₇ and R₈ together with the nitrogen to which they are attached form a 5- to 6-membered ring optionally containing an additional oxygen atom;

X is CH or N;

n is 1;

m is 1 or 2;

o is 0;

p is 0;

q is 1

s is 1 - 2.

5. (Currently Amended) ~~The compound of any of claims 1 to 4 for use as a~~
A medicament comprising the compound of claim 1.

6. (Currently Amended) ~~Use of the compound of any of claims 1 to 4 for the preparation of a medicament for the treatment or prevention of~~ A method of treating or preventing disorders, diseases or conditions responsive to the modulation of the melanocortin-4 receptor in a mammal, where modulation means activation in the case of MC4-R agonists or inactivation in the case of MC4-R antagonists, the method comprising administering to a human or mammal an effective amount of the compound of claim 1.
7. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of cancer cachexia.~~ A method of treating or preventing cancer cachexia, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
8. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of muscle wasting.~~ A method of treating or preventing muscle wasting, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
9. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of anorexia.~~ A method of treating or preventing anorexia, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
10. (Currently Amended) ~~Use of MC4-R antagonists according to claims 6 for the preparation of a medicament for the treatment or prevention of anxiety and/or depression.~~ A method of treating or preventing anxiety and/or depression, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.

11. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of obesity.~~ A method of treating or preventing obesity, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
12. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of diabetes mellitus.~~ A method of treating or preventing diabetes mellitus, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
13. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of male or female sexual dysfunction.~~ A method of treating or preventing male or female sexual dysfunction, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
14. (Currently Amended) ~~Use of MC4-R agonists according to claims 6 for the preparation of a medicament for the treatment or prevention of erectile dysfunction.~~ A method of treating or preventing erectile dysfunction, the method comprising administering to a human or mammal an effective amount of the MC4-R antagonists according to claim 6.
15. (Currently Amended) A pharmaceutical composition which comprises a compound of ~~any of claims 1 to 4~~claim 1 and a pharmaceutically acceptable carrier.